Troy Payner, MD
Neurological Surgery · Carmel, INNPI 1922082866
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $801,156 of the $803,143 with a category attached, or 99.8%. Stryker accounts for 100.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $207,623 and has fallen 65.3% since, to $72,035 in 2025. Among neurological surgery clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $17,088 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$803K
- Kls-martin L.p.$50
- Zimmer Biomet$49
- Johnson & Johnson$46
- UCB, Inc.$29
- Abbott$24
- plus $46 from 3 others
What the payments were for
- Royalty or licence$801,156100%
- Consulting fees$1,5000%
- Food & beverage$4870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 34 | $802,899 |
| Kls-martin L.p. | 3 | $50 |
| Zimmer Biomet | 2 | $49 |
| Johnson & Johnson | 2 | $46 |
| UCB, Inc. | 2 | $29 |
| Abbott | 1 | $24 |
| Aesculap, Inc. | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SONOPET IQ$491,759
- NSE - SONOPET$296,471
- NEPTUNE$12,926
- CORE$1,113
- NA$113
How this compares
$803,143 in reported general payments places this provider in the 95th percentile of 112 neurological surgery providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 32 | $1,453 |
| Carbamazepine | 16 | $1,115 |
| Levetiracetam | 55 | $943 |
| Gabapentin | 31 | $518 |
| Dexamethasone | 21 | $342 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Carmel
- Jean-Pierre MobasserCarmel$3.5M
- Eric PottsCarmel$345K
- Richard RodgersCarmel$45K
- Shahjehan AhmadCarmel$15K
- John DepowellCarmel$15K
- Charles KulwinCarmel$10K
- Daniel KimCarmel$7K
- Kenneth RenkensCarmel$7K
- Saad KhairiCarmel$6K
- Michael TurnerIndianapolis$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.